Mindray laid out ECMO and broke into the "magic lung" circle
On February 14, the Enterprise Investigation APP showed that Shenzhen Hannuo Medical Technology Co., Ltd. underwent industrial and commercial changes, and added Mindray Medical Affiliate Shenzhen Mindray Equity Investment Fund Co., Ltd. as a shareholder, which is a 99% shareholding company of Mindray Medical.
Shenzhen Hannuo Medical Technology Co., Ltd. was founded in 2018 by a number of top medical technology experts studying in Germany; ECMO is considered to be one of the most advanced technologies in the field of emergency care. The mainstream ECMO brands in the domestic market are basically imported, mainly InDonland, Midas, McCovi and Solin in Europe and the United States.
Opening up a new model of targeted RNA, Janssen reached a collaboration of more than $1 billion
On February 17, Remix Therapeutics announced an R&D collaboration with Johnson & Johnson's Janssen to develop small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
As an intermediate of genetic information that connects DNA and proteins, RNA is now considered a key molecule involved in almost all biological pathways. When the researchers discovered the diversity of RNA, they also noticed the advantages of using RNA as a therapeutic molecule.
Another 3 patients died! Bojian Alzheimer's disease drug Aduhelm is controversial
Aduhelm has been controversial since its launch, with 3 more Alzheimer's patients treated with Bohair Aduhelm dying.
Although the specific cause of death of several patients has not yet been determined, the news has also brought renewed attention to the potential safety risks of the controversial drug.
Analysts at RBC Capital (RBC) stressed in a note to investors on Wednesday that whether these patient deaths were related to Aduhelm treatment or were just accidental events remained difficult to distinguish.
First! The FDA approved the new drug for Agios
Today, Agios Pharmaceuticals announced that the U.S. FDA has approved the launch of its new drug, Pyrukynd, for adult patients with pyruvate kinase deficiency and hemolytic anemia. Pyruvate kinase deficiency is a rare class of genetic disorders that cause patients to develop chronic hemolytic anemia.
It is worth mentioning that Pyrukynd is a "first-in-class" oral pyruvate kinase activator.
Gilead's long-acting HIV therapy every 6 months for 1 year yielded positive results
Gilead recently announced the results of the new year of the ongoing Phase II/III CAPELLA trial: for HIV-infected people whose virus is no longer effective in treatment, subcutaneous injection of lenacapavir in combination with other antiretroviral drugs every six months can maintain a high rate of viral suppression and achieve a clinically significant increase in CD4 counts in PEOPLE living with HIV.
83% (n=30/36) of subjects received lenacapavir in combination with an optimized background protocol, achieving undetectable viral load by week 52 (<50 copies/ml).